Researchers at the MUSC Hollings Cancer Center have identified a mechanism that allows prostate cancer cells to survive treatment by hijacking a protein called PIM1. According to a study published in Cancer Letters, traditional therapies that block PIM1 signaling inadvertently trigger a survival response, prompting the team to develop a “degrader” compound known as PIMTAC to destroy the protein entirely rather than just inhibiting it.
Why do prostate cancer cells resist traditional treatment?
Cancer cells often evade chemotherapy and targeted drugs by adapting to stress. Noel Warfel, Ph.D., an associate professor at the Medical University of South Carolina (MUSC), explains that PIM1 acts as a double-edged sword. Standard inhibitors successfully shut down the protein’s kinase signaling activity, but they also cause the cell to accumulate more PIM1. This leftover protein continues to support the tumor through “kinase-independent” survival mechanisms, essentially rendering the drug ineffective over time.
PIM1 is implicated in various cancer types, including breast, lung, and blood cancers. The discovery that cells can survive even when a protein’s primary signaling function is blocked could change how researchers approach drug design for multiple oncological conditions.
How does the PIM1-HMGB1 partnership fuel survival?
The research team discovered that when PIM1 levels rise, the protein binds to HMGB1, a molecule usually found in the cell nucleus. This binding traps HMGB1 in the cell’s cytoplasm, where it triggers autophagy—a cellular recycling process. By using autophagy to clear out damaged mitochondria, cancer cells reduce oxidative stress. According to the study, this process allows the tumor to survive environmental challenges that would typically cause cell death, a finding that explains why some patients stop responding to standard PIM1 inhibitors.
Can “protein degraders” outperform traditional inhibitors?
The study suggests that moving away from simple inhibition toward protein degradation could be more effective. The team’s experimental compound, PIMTAC, is a proteolysis-targeting chimera (PROTAC). Unlike inhibitors that leave the protein intact, PIMTAC targets PIM1 for destruction. In laboratory and mouse models, this approach successfully increased oxidative stress and led to higher rates of cancer cell death, as it removed the protein’s ability to influence the cell through both signaling and non-signaling pathways.
When reviewing cancer treatment research, distinguish between “inhibitors,” which block a protein’s function, and “degraders” (PROTACs), which physically remove the protein from the cell. The latter is increasingly viewed as a solution for proteins that possess “hidden” survival functions.
What are the next steps for clinical application?
While the results in preclinical models are promising, the approach remains in early stages. Before reaching clinical trials, researchers must refine the delivery of the large PROTAC molecule to ensure it reaches tumors accurately throughout the human body. Warfel emphasizes that the findings highlight a broader need to look beyond traditional targets, noting that many cancer-driving proteins have functions that scientists have yet to fully categorize or address with existing drugs.
Frequently Asked Questions
What is the difference between PIM1 inhibitors and PIMTAC?
PIM1 inhibitors only block the chemical signaling of the protein, which can lead to a buildup of the protein that still promotes survival. PIMTAC is a degrader that removes the PIM1 protein from the cell entirely, eliminating both its signaling and non-signaling survival effects.
Is this treatment currently available for patients?
No. The research is currently in the preclinical stage. Further development is required to improve drug delivery systems before it can be tested in human clinical trials.
Does this discovery apply to cancers other than prostate cancer?
Yes. Because PIM proteins are active in various cancers, including breast, lung, and blood cancers, researchers believe these findings could have implications for treating multiple types of solid and liquid tumors.
Are you interested in the latest developments in precision oncology? Subscribe to our newsletter for updates on emerging cancer research and clinical trial advancements. Have questions about this study? Share your thoughts in the comments below.
